BioSpace News Archive

Acceleron Pharma Inc. announced that a total of six distinct abstracts on REBLOZYL® will be presented at the upcoming 2020 American Society of Clinical Oncology 2020 Virtual Scientific Program, held May 29-31, and at the 25th Annual European Hematology Association Virtual Congress, held June 11-21.

Nemaura Medical, Inc. announced its 2020 Omnibus Incentive Plan was approved by shareholder vote at the Company’s Annual General Meeting on May 15, 2020.

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it and its subsidiaries have entered into a $30 million debt facility with Avenue Venture Opportunities Fund, L.P. (Avenue), a fund within the Avenue Capital Group, and its affiliates. “This new debt fa

Trial conducted at Columbia University will investigate potential of chloroquine phosphate to prevent symptomatic SARS-CoV-2 infections

The REIT announces new leases with UMass Lowell and Ora for this strategic location that bolsters IQHQ’s premier life science office and R&D lab space in Greater Boston

Strategic partnership supports CODA’s efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain [20-May-2020] SOUTH SAN FRANCISCO, Calif. , May 20, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today annou

Planned study features noted principal investigator, regulatory flexibility, and immediate availability of patients

Second Product Offering to Expand Disease Management within Enzo’s Comprehensive COVID-19 Program Enzo’s ELISA Kit for SARS-CoV-2 IgG Antibody Demonstrates High Specificity and High Sensitivity Detection NEW YORK, NY, May 20, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it is currently offering a SARS-CoV-2 IgG ELISA assay kit for serological detection of IgG antibodies against the novel coronavirus under th

KBP-5074, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Under Evaluation for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease (CKD) Patients Top Line Data Expected Fourth Quarter 2020 PRINCETON, N.J., May 20, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical stage biotechnology company dedicated to research, development and commercialization of innovative medicines for the global market, today announced that it has completed patient enrollment

Pathnostics, a diagnostic solutions company, today announced that it has launched a COVID-19 polymerase chain reaction (PCR) laboratory test designed to support U.S. health care workers in their efforts to keep their patients, colleagues and workplaces safe.